Crizotinib in the treatment of non-small-cell lung carcinoma

Recent studies have demonstrated the benefit of EGFR tyrosine kinase inhibitors in the treatment of advanced non-small-cell lung cancer (NSCLC). The role of activation of the anaplastic lymphoma kinase (ALK) pathway and the presence of the fusion gene EML4-ALK are new molecular targets in studies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Płużański, Adam, Piórek, Aleksandra, Krzakowski, Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687470/
https://www.ncbi.nlm.nih.gov/pubmed/23788933
http://dx.doi.org/10.5114/wo.2012.32477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687470/
https://www.ncbi.nlm.nih.gov/pubmed/23788933
http://dx.doi.org/10.5114/wo.2012.32477

Ejemplares similares